Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on October 24, 2017, reporting events occurring on October 19, 2017. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change is the execution of an Amended and Restated Employment Agreement with Leonard L. Mazur, the Company's Secretary and Executive Chairman of the Board. Key terms include:
- Compensation: Annual salary of $250,000 with eligibility for an annual bonus of up to 50% of the salary, contingent on financial, clinical, and business milestones.
- Term: A three-year initial term ending October 19, 2020, with automatic one-year renewals unless terminated.
- Termination Provisions:
- Without Cause/Good Reason: 12 months of salary and benefits, plus immediate vesting of options that would have vested at the next event.
- Change of Control: If terminated within 90 days prior to or 2 years following a Change of Control, the executive receives 18 months of salary, 18 months of benefits, and full acceleration of all unvested stock options.
- Disability: Full salary for up to 90 consecutive days or 180 days in aggregate within a 12-month period.
- Board Appointment: The Company agreed to use best efforts to elect Mr. Mazur to the Board of Directors during the agreement term without additional director compensation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential financial impact of the executive compensation package, particularly the acceleration of equity awards and severance payments in the event of a Change of Control or termination without Cause.
Investor Verification Checklist
- Verify the total number of unvested stock options held by Mr. Mazur to assess potential dilution upon termination or Change of Control.
- Review the specific financial and clinical milestones required to trigger the 50% annual bonus.
- Confirm the Company's current cash position to evaluate its ability to fund the severance obligations (12 to 18 months of salary) if triggered.
- Check the upcoming stockholders meeting schedule to confirm Mr. Mazur's nomination to the Board.